| pubmed-article:10471426 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:10471426 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:10471426 | lifeskim:mentions | umls-concept:C0948008 | lld:lifeskim |
| pubmed-article:10471426 | lifeskim:mentions | umls-concept:C0036043 | lld:lifeskim |
| pubmed-article:10471426 | lifeskim:mentions | umls-concept:C0205178 | lld:lifeskim |
| pubmed-article:10471426 | lifeskim:mentions | umls-concept:C2603343 | lld:lifeskim |
| pubmed-article:10471426 | lifeskim:mentions | umls-concept:C0140182 | lld:lifeskim |
| pubmed-article:10471426 | lifeskim:mentions | umls-concept:C1512523 | lld:lifeskim |
| pubmed-article:10471426 | pubmed:issue | 9 | lld:pubmed |
| pubmed-article:10471426 | pubmed:dateCreated | 1999-10-8 | lld:pubmed |
| pubmed-article:10471426 | pubmed:abstractText | Remacemide hydrochloride and its principal active desglycinyl metabolite are low-affinity noncompetitive N-methyl-D-aspartate (NMDA)-receptor channel blockers. Remacemide hydrochloride has demonstrated neuroprotection in animal models of hypoxia and ischemic stroke. This study assessed the safety, tolerability, and pharmacokinetics of ascending doses of remacemide hydrochloride in patients with recent onset (within 12 hours) ischemic stroke. | lld:pubmed |
| pubmed-article:10471426 | pubmed:language | eng | lld:pubmed |
| pubmed-article:10471426 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10471426 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:10471426 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10471426 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10471426 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10471426 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10471426 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:10471426 | pubmed:month | Sep | lld:pubmed |
| pubmed-article:10471426 | pubmed:issn | 0039-2499 | lld:pubmed |
| pubmed-article:10471426 | pubmed:author | pubmed-author:LeesK RKR | lld:pubmed |
| pubmed-article:10471426 | pubmed:author | pubmed-author:DykerA GAG | lld:pubmed |
| pubmed-article:10471426 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:10471426 | pubmed:volume | 30 | lld:pubmed |
| pubmed-article:10471426 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:10471426 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:10471426 | pubmed:pagination | 1796-801 | lld:pubmed |
| pubmed-article:10471426 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:10471426 | pubmed:meshHeading | pubmed-meshheading:10471426... | lld:pubmed |
| pubmed-article:10471426 | pubmed:meshHeading | pubmed-meshheading:10471426... | lld:pubmed |
| pubmed-article:10471426 | pubmed:meshHeading | pubmed-meshheading:10471426... | lld:pubmed |
| pubmed-article:10471426 | pubmed:meshHeading | pubmed-meshheading:10471426... | lld:pubmed |
| pubmed-article:10471426 | pubmed:meshHeading | pubmed-meshheading:10471426... | lld:pubmed |
| pubmed-article:10471426 | pubmed:meshHeading | pubmed-meshheading:10471426... | lld:pubmed |
| pubmed-article:10471426 | pubmed:meshHeading | pubmed-meshheading:10471426... | lld:pubmed |
| pubmed-article:10471426 | pubmed:meshHeading | pubmed-meshheading:10471426... | lld:pubmed |
| pubmed-article:10471426 | pubmed:meshHeading | pubmed-meshheading:10471426... | lld:pubmed |
| pubmed-article:10471426 | pubmed:meshHeading | pubmed-meshheading:10471426... | lld:pubmed |
| pubmed-article:10471426 | pubmed:meshHeading | pubmed-meshheading:10471426... | lld:pubmed |
| pubmed-article:10471426 | pubmed:meshHeading | pubmed-meshheading:10471426... | lld:pubmed |
| pubmed-article:10471426 | pubmed:meshHeading | pubmed-meshheading:10471426... | lld:pubmed |
| pubmed-article:10471426 | pubmed:meshHeading | pubmed-meshheading:10471426... | lld:pubmed |
| pubmed-article:10471426 | pubmed:meshHeading | pubmed-meshheading:10471426... | lld:pubmed |
| pubmed-article:10471426 | pubmed:meshHeading | pubmed-meshheading:10471426... | lld:pubmed |
| pubmed-article:10471426 | pubmed:meshHeading | pubmed-meshheading:10471426... | lld:pubmed |
| pubmed-article:10471426 | pubmed:year | 1999 | lld:pubmed |
| pubmed-article:10471426 | pubmed:articleTitle | Remacemide hydrochloride: a double-blind, placebo-controlled, safety and tolerability study in patients with acute ischemic stroke. | lld:pubmed |
| pubmed-article:10471426 | pubmed:affiliation | Acute Stroke Unit, University Department of Medicine and Therapeutics, Gardiner Institute, Western Infirmary, Glasgow, G11 6NT Scotland, UK. AD47Qclinmed.gla.ac.uk | lld:pubmed |
| pubmed-article:10471426 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:10471426 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:10471426 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:10471426 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
